Biogaia AB
STO:BIOG B
Biogaia AB
BioGaia AB engages in the development, marketing, and sale of probiotic products. The company is headquartered in Stockholm, Stockholm. The firm develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The firm operates worldwide.
BioGaia AB engages in the development, marketing, and sale of probiotic products. The company is headquartered in Stockholm, Stockholm. The firm develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics segment drops, gut health tablets, oral rehydration solution (ORS) and cultures to be used as ingredients in licensee products; The Adult Health segment (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee’s dairy products) and the Other (royalties in respect of development projects, revenue from packaging solutions in the subsidiary CapAble, etc.). The firm operates worldwide.
Strong Sales Growth: BioGaia reported Q4 sales of SEK 365 million, up 23% year-on-year, with regional growth led by the Americas (+32%), EMEA (+24%), and Asia Pacific (+10%).
Profitability: Operating profit (EBIT) grew 28% to SEK 103 million, with an EBIT margin of 28% for the quarter.
Gross Margin Decline: Gross margin dropped to 71% from 76% last year, with Pediatrics especially impacted due to inventory write-downs and sales mix.
Dividend Proposal: Board proposed a total dividend of SEK 6.90 per share, totaling SEK 698 million.
Product Launches: New products included BioGaia Gastrus PURE ACTION and expanded launches in several markets.
Direct Sales Strategy: BioGaia is increasing direct market operations, including plans to take French distribution in-house.
Market Outperformance: Quarterly results exceeded market expectations.
